{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:45:54Z","timestamp":1792205154207,"version":"4.4.0"},"reference-count":94,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The emergence or re-emergence of viruses with epidemic and\/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.<\/jats:p>","DOI":"10.3390\/v13040667","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T05:31:37Z","timestamp":1618291897000},"page":"667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":211,"title":["Broad-Spectrum Antiviral Strategies and Nucleoside Analogues"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6509","authenticated-orcid":false,"given":"Robert","family":"Geraghty","sequence":"first","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9149","authenticated-orcid":false,"given":"Matthew","family":"Aliota","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-8822","authenticated-orcid":false,"given":"Laurent","family":"Bonnac","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, Devices, and the FDA: Part 1","volume":"1","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/769121","article-title":"Ebola Virus Disease 2013\u20132014 Outbreak in West Africa: An Analysis of the Epidemic Spread and Response","volume":"2015","author":"Cenciarelli","year":"2015","journal-title":"Int. J. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12985-015-0439-5","article-title":"MERS coronavirus: Diagnostics, epidemiology and transmission","volume":"12","author":"Mackay","year":"2015","journal-title":"Virol. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3855\/jidc.12671","article-title":"The novel zoonotic COVID-19 pandemic: An expected global health concern","volume":"14","author":"Contini","year":"2020","journal-title":"J. Infect. Dev. Countries"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chowell, G., Echevarr\u00eda-Zuno, S., Viboud, C., Simonsen, L., Tamerius, J., Miller, M.A., Borja-Aburto, V.H., and Peiris, J.S.M. (2011). Characterizing the Epidemiology of the 2009 Influenza A\/H1N1 Pandemic in Mexico. PLoS Med., 8.","DOI":"10.1371\/journal.pmed.1000436"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13071-018-2830-8","article-title":"History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: A review","volume":"11","author":"Salles","year":"2018","journal-title":"Parasites Vectors"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1590\/0074-02760150192","article-title":"First report of autochthonous transmission of Zika virus in Brazil","volume":"110","author":"Zanluca","year":"2015","journal-title":"Mem\u00f3rias Do Inst. Oswaldo Cruz."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika Virus and Birth Defects\u2014Reviewing the Evidence for Causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Barrett, A.D.T. (2018). West Nile in Europe: An increasing public health problem. J. Travel Med., 25.","DOI":"10.1093\/jtm\/tay096"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.actatropica.2016.11.020","article-title":"The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers","volume":"166","author":"Mayer","year":"2017","journal-title":"Acta Trop."},{"key":"ref_13","first-page":"30048","article-title":"The consequences of human actions on risks for infectious diseases: A review","volume":"5","author":"Lindahl","year":"2015","journal-title":"Infect. Ecol. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145413","DOI":"10.1016\/j.scitotenv.2021.145413","article-title":"Shifts in global bat diversity suggest a possible role of climate change in the emergence of SARS-CoV-1 and SARS-CoV-2","volume":"767","author":"Beyer","year":"2021","journal-title":"Sci. Total Environ."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pronker, E.S., Weenen, T.C., Commandeur, H., Claassen, E.H.J.H.M., Osterhaus, A.D.M.E., and Vasilakis, N. (2013). Risk in Vaccine Research and Development Quantified. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057755"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug Repurposing for Viral Infectious Diseases: How Far Are We?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2006.03.005","article-title":"Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics","volume":"72","author":"Balzarini","year":"2006","journal-title":"Antiviral Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sz\u0171cs, Z., Naesens, L., Stevaert, A., Ostorh\u00e1zi, E., Batta, G., Herczegh, P., and Borb\u00e1s, A. (2020). Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity. Pharmaceuticals., 13.","DOI":"10.3390\/ph13070139"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","volume":"40","author":"Ji","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Saiz, J.-C., Oya, N.J.d., Bl\u00e1zquez, A.-B., Escribano-Romero, E., Mart\u00edn-Acebes, M.A., Oya, N., and Mart\u00edn-Acebes, M. (2018). Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus. Viruses, 10.","DOI":"10.20944\/preprints201807.0359.v1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/jm00286a024","article-title":"Novel substrate of adenosine deaminase","volume":"14","author":"Schaeffer","year":"1971","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/CMR.8.2.200","article-title":"Antiviral therapy for human immunodeficiency virus infections","volume":"8","year":"1995","journal-title":"Clin. Microbiol. Rev. Cmr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0163-7258(00)00050-4","article-title":"Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors","volume":"87","author":"Balzarini","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"ref_26","first-page":"704","article-title":"Antivirals and antiviral strategies","volume":"2","author":"Clercq","year":"2004","journal-title":"Nat. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold","volume":"154","author":"Yates","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2018.11.016","article-title":"The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold","volume":"162","author":"Yates","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"204020661876129","DOI":"10.1177\/2040206618761299","article-title":"Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses","volume":"26","author":"Eyer","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_30","first-page":"11","article-title":"Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians","volume":"21","author":"Stein","year":"2001","journal-title":"Pharmacother. Off. J. Am. Coll. Clin. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","article-title":"A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties","volume":"48","author":"Olsen","year":"2004","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-405880-4.00002-0","article-title":"Nucleotide Prodrugs for the Treatment of HCV Infection","volume":"67","author":"Sofia","year":"2013","journal-title":"Anti-Viral Agents"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.38.7.1573","article-title":"Differential antiviral activities and intracellular metabolism of 3\u2019-azido-3\u2019-deoxythymidine and 2\u2019,3\u2019-dideoxyinosine in human cells","volume":"38","author":"Mukherji","year":"1994","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm0897-922","article-title":"The bottleneck in AZT activation","volume":"3","author":"Lavie","year":"1997","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.antiviral.2009.10.020","article-title":"Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2\u2032-C-methyl-cytidine to its 5\u2032-monophosphate metabolite","volume":"85","author":"Golitsina","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1021\/jm0491400","article-title":"Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency","volume":"48","author":"McGuigan","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1016\/j.bmcl.2009.05.099","article-title":"The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4\u2032-azidocytidine (R1479)","volume":"19","author":"McGuigan","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1016\/j.bmcl.2009.05.122","article-title":"The phosphoramidate ProTide approach greatly enhances the activity of \u03b2-2\u2032-C-methylguanosine against hepatitis C virus","volume":"19","author":"McGuigan","year":"2009","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/03639040701836636","article-title":"Physicochemical Properties of the Nucleoside Prodrug R1626 Leading to High Oral Bioavailability","volume":"34","author":"Brandl","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"Feldmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Malin, J.J., Su\u00e1rez, I., Priesner, V., F\u00e4tkenheuer, G., and Rybniker, J. (2020). Remdesivir against COVID-19 and Other Viral Diseases. Clin. Microbiol. Rev. Cmr., 34.","DOI":"10.1128\/CMR.00162-20"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tchesnokov, E.P., Feng, J.Y., Porter, D.P., G\u00f6tte, M., Tchesnokov, E., Feng, J., and Porter, D. (2019). Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 11.","DOI":"10.3390\/v11040326"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1073\/pnas.1201130109","article-title":"RNA 3\u2019-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex","volume":"109","author":"Bouvet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.ajogmf.2020.100164","article-title":"Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center","volume":"2","author":"McCoy","year":"2020","journal-title":"Am. J. Obstet. Gynecol. Mfm."},{"key":"ref_53","first-page":"659","article-title":"Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacother. Off. J. Am. Coll. Clin. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40261-018-0624-6","article-title":"Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies","volume":"38","author":"Ferreira","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1590\/s1678-9946201961012","article-title":"Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: Case report and review","volume":"61","author":"Mucenic","year":"2019","journal-title":"Rev. Do Inst. De Med. Trop. De S\u00e3o Paulo J. S\u00e3o Paulo Inst. Trop. Med. Publ. Inst. De Med. Trop."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eimc.2018.05.008","article-title":"Uso de ribavirina en virus distintos de la hepatitis C. Una revisi\u00f3n de la evidencia","volume":"37","author":"Membrillo","year":"2019","journal-title":"Enferm. Infecc. Y Microbiol. Cl\u00ednica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa Fever","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1073\/pnas.75.7.3042","article-title":"Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line","volume":"75","author":"Willis","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0162-3109(00)00193-4","article-title":"The structure of inosine 5\u2032-monophosphate dehydrogenase and the design of novel inhibitors","volume":"47","author":"Sintchak","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","article-title":"The antiviral compound ribavirin modulates the T helper (Th) 1\/Th2 subset balance in hepatitis B and C virus-specific immune responses","volume":"79","author":"Hultgren","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/newbio244116a0","article-title":"A New Class of Synthetic Nucleoside Analogues with Broad-spectrum Antiviral Properties","volume":"244","author":"Prusiner","year":"1973","journal-title":"Nat. New Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0406927102","article-title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","volume":"101","author":"Kentsis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","article-title":"Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate","volume":"11","author":"Eriksson","year":"1977","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/AAC.32.4.492","article-title":"Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription","volume":"32","author":"Toltzis","year":"1988","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","article-title":"Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection","volume":"139","author":"Kamar","year":"2010","journal-title":"Gastroenterology."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: Direct molecular test by using ribavirin","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1073\/pnas.96.24.13910","article-title":"Mutation rates among RNA viruses","volume":"96","author":"Drake","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanjuan","year":"2010","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1096\/fasebj.10.8.8666162","article-title":"Basic concepts in RNA virus evolution","volume":"10","author":"Domingo","year":"1996","journal-title":"FASEB J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0378-1119(92)90216-C","article-title":"Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase","volume":"122","author":"Steinhauer","year":"1992","journal-title":"Gene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/jvi.64.8.3960-3962.1990","article-title":"Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis","volume":"64","author":"Holland","year":"1990","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0006-2952(77)90246-5","article-title":"Virazole (1-\u03b2-d-ribofuranosyl-1,2,4-triazole-3-carboxamide; A cytostatic agent","volume":"26","author":"Maidhof","year":"1977","journal-title":"Biochem. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Qiu, L., Patterson, S.E., Bonnac, L.F., and Geraghty, R.J. (2018). Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006421"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., and Deval, J. (2013). The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068347"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother. Aac."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","article-title":"Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs","volume":"143","author":"Jin","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","article-title":"Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: A case-series of health-care workers","volume":"15","author":"Jacobs","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Taburet","year":"2015","journal-title":"Lancet. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H., Guedj, J., Anglaret, X., Laouenan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces. India"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1021\/jm400653j","article-title":"Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis","volume":"56","author":"Bonnac","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:47:17Z","timestamp":1760161637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["v13040667"],"URL":"https:\/\/doi.org\/10.3390\/v13040667","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}